Adell Harriman & Carpenter Inc. Trims Stock Holdings in Danaher Co. (NYSE:DHR)

Adell Harriman & Carpenter Inc. cut its stake in Danaher Co. (NYSE:DHR) by 14.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,649 shares of the conglomerate’s stock after selling 2,356 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in Danaher were worth $3,158,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. BKM Wealth Management LLC acquired a new stake in Danaher during the 4th quarter worth about $27,000. Wetzel Investment Advisors Inc. acquired a new stake in Danaher during the 4th quarter worth about $29,000. OFI Invest Asset Management acquired a new stake in Danaher during the 3rd quarter worth about $30,000. Rakuten Securities Inc. purchased a new position in shares of Danaher during the 4th quarter valued at about $36,000. Finally, BluePath Capital Management LLC purchased a new position in shares of Danaher during the 3rd quarter valued at about $44,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on DHR shares. Bank of America lifted their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Citigroup lifted their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Royal Bank of Canada increased their target price on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Finally, Raymond James increased their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $269.64.

Danaher Trading Up 0.1 %

Danaher stock traded up $0.24 during mid-day trading on Monday, hitting $246.82. The company’s stock had a trading volume of 1,616,167 shares, compared to its average volume of 2,771,678. The firm has a market capitalization of $182.82 billion, a PE ratio of 42.12, a price-to-earnings-growth ratio of 3.80 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The stock’s fifty day moving average is $248.87 and its two-hundred day moving average is $231.27.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.36 earnings per share. On average, analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Wednesday, March 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Transactions at Danaher

In other news, EVP Joakim Weidemanis sold 22,433 shares of the firm’s stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the completion of the transaction, the executive vice president now directly owns 90,412 shares in the company, valued at $22,644,589.52. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, EVP Joakim Weidemanis sold 22,433 shares of the firm’s stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the completion of the transaction, the executive vice president now directly owns 90,412 shares in the company, valued at $22,644,589.52. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Insiders sold a total of 106,565 shares of company stock worth $26,641,364 over the last ninety days. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.